Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
Public ClinicalTrials.gov record NCT05496686. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
First in Human Phase I Study of 225Actinium-MTI-201 (225Ac-MTI-201) in Metastatic Uveal Melanoma
Study identification
- NCT ID
- NCT05496686
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Modulation Therapeutics, Inc.
- Industry
- Enrollment
- 16 participants
Conditions and interventions
Conditions
Interventions
- 1327 microCi of 225Ac-MTI-201 Drug
- 152 microCi of 225Ac-MTI-201 Drug
- 19 microCi of 225Ac-MTI-201 Drug
- 254 microCi of 225Ac-MTI-201 Drug
- 38 microCi of 225Ac-MTI-201 Drug
- 4.7 microCi 225Ac-MTI-201 Drug
- 424 microCi of 225Ac-MTI-201 Drug
- 564 microCi of 225Ac-MTI-201 Drug
- 750 microCi of 225Ac-MTI-201 Drug
- 76 microCi of 225Ac-MTI-201 Drug
- 9.5 microCi of 225Ac-MTI-201 Drug
- 998 microCi of 225Ac-MTI-201 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 20, 2022
- Primary completion
- Mar 30, 2027
- Completion
- Feb 24, 2029
- Last update posted
- Apr 2, 2026
2022 – 2029
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| H. Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05496686, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 2, 2026 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05496686 live on ClinicalTrials.gov.